science pharmaceutical expo biotech jobs
Originally published online as doi:10.1189/jlb.1004564 on April 27, 2005

Published online before print April 27, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.1004564v1
78/2/491    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gomariz, R. P.
Right arrow Articles by Juarranz, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gomariz, R. P.
Right arrow Articles by Juarranz, Y.
(Journal of Leukocyte Biology. 2005;78:491-502.)
© 2005 by Society for Leukocyte Biology

Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP

Rosa P. Gomariz*,1, Alicia Arranz*, Catalina Abad*, Marta Torroba*, Carmen Martinez{dagger}, Florencia Rosignoli*, Maria Garcia-Gómez*, Javier Leceta* and Yasmina Juarranz*

* Department of Cell Biology, Faculties of Biology and
{dagger} Medicine, Complutense University, Madrid, Spain

1 Correspondence: Departamento de Biología Celular, Facultad de Biología, Universidad Complutense, 28040 Madrid, Spain. E-mail: gomariz{at}bio.ucm.es

Toll-like receptor 2 (TLR2) and -4 mediate signals from a great variety of bacterial gut products, giving the host a panel of microbe-recognizing receptors. Under homeostatic conditions, TLRs act as protective receptors of the intestinal epithelium. When homeostasis is disrupted in diseases such as inflammatory bowel disease, TLR2 and -4 are deregulated. Our study demonstrates, by using a trinitrobenzene sulfonic acid-induced colitis model of Crohn’s disease, the constitutive expression and the up-regulation of TLR2 and -4 at messenger and protein levels in colon extracts, as well as in macrophages, dendritic cells, and lymphocytes from mesenteric lymphoid nodes. Vasoactive intestinal peptide (VIP) treatment induced a decrease of TLR2 and -4 expressions approaching ethanol control levels. Our results suggest that VIP modulation of TLR2 and -4 could be explained by two possible mechanisms. The first one would be the secondary reduction of TLR2 and -4 caused by the VIP-mediated decrease of inflammatory mediators such as interleukin-1ß and interferon- {gamma}, which synergize with bacterial products, contributing to the amplification of TLR presence in the intestine. The other possible mechanism would involve a VIP-mediated decrease of nuclear factor-{kappa}B, which would cause a direct down-regulation of TLR expression. In summary, the resultant physiological effect is the decrease of TLR2 and -4 expressions to homeostatic levels. Our study describes for the first time the role of a peptide present in the gut microenvironment as an effective modulator of the initial steps of acute inflammation, acting at local and systemic levels and leading to the restoration of the homeostasis lost after an established inflammatory/autoimmune disease.

Key Words: immunomodulation • inflammation • homeostasis




This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
S. C. Gribar, R. J. Anand, C. P. Sodhi, and D. J. Hackam
The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation
J. Leukoc. Biol., March 1, 2008; 83(3): 493 - 498.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
J. S. Bryson, C. D. Jennings, J. A. Brandon, J. Perez, B. E. Caywood, and A. M. Kaplan
Adoptive transfer of murine syngeneic graft-vs.-host disease by CD4+ T cells
J. Leukoc. Biol., December 1, 2007; 82(6): 1393 - 1400.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
E. Gonzalez-Rey, P. Anderson, and M. Delgado
Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy
Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii70 - iii76.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
H. F. Rosenberg
Vasoactive intestinal peptide, periodontal disease, and the innate immune response: an interview with Dr. John J. Taylor
J. Leukoc. Biol., April 1, 2007; 81(4): 904 - 906.
[Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
N. Foster, S. R. Lea, P. M. Preshaw, and J. J. Taylor
Pivotal Advance: Vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages
J. Leukoc. Biol., April 1, 2007; 81(4): 893 - 903.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. M. Szema, S. A. Hamidi, S. Lyubsky, K. G. Dickman, S. Mathew, T. Abdel-Razek, J. J. Chen, J. A. Waschek, and S. I. Said
Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP
Am J Physiol Lung Cell Mol Physiol, November 1, 2006; 291(5): L880 - L886.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
I. Gutierrez-Canas, Y. Juarranz, B. Santiago, A. Arranz, C. Martinez, M. Galindo, M. Paya, R. P. Gomariz, and J. L. Pablos
VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts
Rheumatology, May 1, 2006; 45(5): 527 - 532.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Chorny, E. Gonzalez-Rey, A. Fernandez-Martin, D. Pozo, D. Ganea, and M. Delgado
Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders
PNAS, September 20, 2005; 102(38): 13562 - 13567.
[Abstract] [Full Text] [PDF]